BRPI0708101A8 - anticorpos contra a il-22 humana e usos para eles - Google Patents

anticorpos contra a il-22 humana e usos para eles

Info

Publication number
BRPI0708101A8
BRPI0708101A8 BRPI0708101A BRPI0708101A BRPI0708101A8 BR PI0708101 A8 BRPI0708101 A8 BR PI0708101A8 BR PI0708101 A BRPI0708101 A BR PI0708101A BR PI0708101 A BRPI0708101 A BR PI0708101A BR PI0708101 A8 BRPI0708101 A8 BR PI0708101A8
Authority
BR
Brazil
Prior art keywords
antibodies
human
disorders
allergies
antagonists
Prior art date
Application number
BRPI0708101A
Other languages
English (en)
Inventor
B Thom Albert
S Russell Caroline
C Lowe David
S Gill Davinder
M Veldman Geertruida
Li Jing
A Fouser Lynette
Limited Medimmune
R Minter Ralph
E Cohen Suzanne
Valge-Archer Viia
Original Assignee
Wyeth Corp
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38236225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0708101(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Wyeth Llc filed Critical Wyeth Corp
Publication of BRPI0708101A2 publication Critical patent/BRPI0708101A2/pt
Publication of BRPI0708101A8 publication Critical patent/BRPI0708101A8/pt
Publication of BRPI0708101B1 publication Critical patent/BRPI0708101B1/pt
Publication of BRPI0708101B8 publication Critical patent/BRPI0708101B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpos contra a il-22 humana e usos para eles. a presente invenção refere-se a anticorpos humanos e fragmentos dos mesmos de ligação a antígenos que especificamente se ligam à interleucina-22 (il-22) humana. os anticorpos podem atuar como antagonistas da atividade da il-22, com isso modulando as respostas imunes, em geral, e aquelas mediadas pela il-22, em particular. as composições e os métodos descritos podem ser usados, por exemplo, no diagnóstico, no tratamento ou na prevenção de distúrbios inflamatórios, doenças auto-imunes, alergias, choque séptico, distúrbios infecciosos, rejeição ao transplante, câncer, e outros distúrbios do sistema imune.
BRPI0708101A 2006-02-21 2007-02-21 anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico BRPI0708101B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77459606P 2006-02-21 2006-02-21
US60/774,596 2006-02-21
PCT/US2007/004430 WO2007098170A1 (en) 2006-02-21 2007-02-21 Antibodies against human il-22 and uses therefor

Publications (4)

Publication Number Publication Date
BRPI0708101A2 BRPI0708101A2 (pt) 2011-05-17
BRPI0708101A8 true BRPI0708101A8 (pt) 2019-01-22
BRPI0708101B1 BRPI0708101B1 (pt) 2020-01-14
BRPI0708101B8 BRPI0708101B8 (pt) 2021-05-25

Family

ID=38236225

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0708101A BRPI0708101B8 (pt) 2006-02-21 2007-02-21 anticorpo, ou seu fragmento de ligação a antígeno, que especificamente se liga a il-22, composição farmacêutica, ácido nucléico isolado, vetor de expressão, célula hospedeira, método de produção do mesmo e kit diagnóstico

Country Status (31)

Country Link
US (4) US7901684B2 (pt)
EP (3) EP1991584B1 (pt)
JP (1) JP5150516B2 (pt)
KR (2) KR20080113214A (pt)
CN (1) CN101426816B (pt)
AR (1) AR059604A1 (pt)
AT (1) ATE538137T1 (pt)
AU (1) AU2007217751B2 (pt)
BR (1) BRPI0708101B8 (pt)
CA (1) CA2643226C (pt)
CR (1) CR10237A (pt)
DK (2) DK3020729T3 (pt)
EC (1) ECSP088751A (pt)
ES (2) ES2377463T3 (pt)
HN (1) HN2008001292A (pt)
HU (1) HUE044595T2 (pt)
IL (1) IL193605A (pt)
MX (2) MX337778B (pt)
MY (1) MY146664A (pt)
NO (1) NO20083715L (pt)
NZ (1) NZ570878A (pt)
PE (1) PE20080111A1 (pt)
PL (2) PL3020729T3 (pt)
PT (2) PT1991584E (pt)
RU (1) RU2467016C2 (pt)
SA (1) SA07280062B1 (pt)
SG (1) SG172628A1 (pt)
SI (2) SI3020729T1 (pt)
TW (1) TWI417301B (pt)
WO (1) WO2007098170A1 (pt)
ZA (1) ZA200807278B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295026T3 (es) * 1999-04-28 2008-04-16 Genetics Institute, Llc Proteinas gil-19/ae289 humanas y polinucleotidos que codifican las mismas.
WO2007126439A2 (en) * 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
RU2011105466A (ru) * 2008-08-28 2012-10-10 ВАЙЕТ ЭлЭлСи (US) Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
EP2419733A4 (en) 2009-04-13 2013-12-25 Univ Leland Stanford Junior METHOD AND DEVICES FOR DETECTING THE PRESENCE OF AN ANALYZES IN A SAMPLE
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
JP5937019B2 (ja) * 2010-03-12 2016-06-22 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 磁気センサに基づく結合反応速度の定量的な分析
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US9221904B2 (en) * 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
IN2015DN00140A (pt) * 2012-08-31 2015-06-12 Argen X Bv
EP2970422B1 (en) 2013-03-15 2018-04-18 F.Hoffmann-La Roche Ag Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CN105139918B (zh) * 2015-06-26 2017-04-12 哈尔滨工业大学 一种柔板印刷用低银高性能导电浆料及其制备方法
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
WO2018039107A1 (en) * 2016-08-22 2018-03-01 Medimmune, Llc Binding molecules specific for notch4 and uses thereof
CN110402393A (zh) * 2016-11-24 2019-11-01 休伯特保健公司 疾病诊断的组合物
TW202323287A (zh) 2016-11-28 2023-06-16 日商中外製藥股份有限公司 包含抗原結合域與運送部分的多胜肽
TWI776827B (zh) 2016-11-28 2022-09-11 日商中外製藥股份有限公司 能夠調節配體結合活性的配體結合分子
MX2020005220A (es) 2017-11-28 2020-08-24 Chugai Pharmaceutical Co Ltd Polipeptido que incluye dominio de union al antigeno y seccion de transporte.
US12195528B2 (en) 2017-11-28 2025-01-14 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand-binding activity
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
KR20210019464A (ko) * 2018-06-05 2021-02-22 바이오아트라, 인코퍼레이티드 항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
CA3113948A1 (en) * 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물
EP4255926A1 (en) * 2020-12-07 2023-10-11 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
KR20230118128A (ko) 2020-12-07 2023-08-10 유씨비 바이오파마 에스알엘 인터루킨-22에 대한 항체
KR20230165212A (ko) 2021-03-02 2023-12-05 다나-파버 캔서 인스티튜트 인크. 적혈구 장애의 치료 방법
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
EP1498427B1 (en) 1992-08-21 2009-12-16 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
WO1997039772A1 (fr) * 1996-04-19 1997-10-30 Chugai Seiyaku Kabushiki Kaisha Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6492507B1 (en) * 1996-10-23 2002-12-10 Incyte Genomics, Inc. Polynucleotides encoding human eosinophil-derived basic protein
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO2002016611A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
ES2386262T3 (es) * 1998-01-23 2012-08-14 F. Hoffmann-La Roche Ag Anticuerpos contra IL-12 humana
AU4208799A (en) * 1998-05-29 1999-12-13 Human Genome Sciences, Inc. Interleukins-21 and 22
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
CN1238367C (zh) * 1998-10-26 2006-01-25 路德维格癌症研究院 分离的编码t细胞诱导因子(tif)的核酸分子,其编码蛋白及其应用
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
CA2796140A1 (en) 1999-03-25 2000-09-28 Jochen Salfeld Human antibodies that bind human il-12 and methods for producing
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7307161B1 (en) * 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
AU5151100A (en) * 1999-05-19 2000-12-05 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1208195A2 (en) 1999-06-15 2002-05-29 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1234035B1 (en) * 1999-12-03 2010-02-24 ZymoGenetics, Inc. Human cytokine receptor
WO2001046422A1 (en) 1999-12-23 2001-06-28 Zymogenetics, Inc. Novel cytokine zcyto18
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
WO2001055112A1 (en) 2000-01-27 2001-08-02 American Cyanamid Company Method for preparing alpha-sulfonyl hydroxamic acid derivatives
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
CN100448994C (zh) 2000-07-27 2009-01-07 惠氏公司 分离的编码t细胞诱导因子或白介素-21的核酸分子,其编码的蛋白和其应用
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US7094570B2 (en) * 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
JP2005510451A (ja) 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー 炎症性障害を治療するための組成物及び方法
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20020187512A1 (en) 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
US7265211B2 (en) * 2002-03-22 2007-09-04 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of making
ATE518884T1 (de) * 2002-05-01 2011-08-15 Human Genome Sciences Inc Spezifisch an chemokin beta-4 bindende antikörper
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
RU2006101702A (ru) * 2003-06-23 2006-09-10 Дженетикс Инститьют, Ллс (Us) Антитела против интерлейкина-22 и их применения
CA2612746A1 (en) 2005-07-04 2007-01-11 Samsung Electronics Co., Ltd. Position measuring system and method using wireless broadband (wibro) signal
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation

Also Published As

Publication number Publication date
PE20080111A1 (es) 2008-02-20
RU2467016C2 (ru) 2012-11-20
ECSP088751A (es) 2008-11-27
TW200801041A (en) 2008-01-01
EP2431392B1 (en) 2015-09-09
EP1991584B1 (en) 2011-12-21
EP2431392A1 (en) 2012-03-21
SI1991584T1 (sl) 2012-05-31
US7901684B2 (en) 2011-03-08
US8182817B2 (en) 2012-05-22
US20070243589A1 (en) 2007-10-18
BRPI0708101B1 (pt) 2020-01-14
ES2377463T3 (es) 2012-03-27
TWI417301B (zh) 2013-12-01
SG172628A1 (en) 2011-07-28
ATE538137T1 (de) 2012-01-15
US20100184960A1 (en) 2010-07-22
MX337778B (es) 2016-03-18
PT3020729T (pt) 2019-08-06
CA2643226A1 (en) 2007-08-30
PL1991584T3 (pl) 2012-05-31
MY146664A (en) 2012-09-14
NO20083715L (no) 2008-11-06
KR20080113214A (ko) 2008-12-29
EP3020729A1 (en) 2016-05-18
EP3020729B1 (en) 2019-06-26
HN2008001292A (es) 2012-02-13
PL3020729T3 (pl) 2019-12-31
EP1991584A1 (en) 2008-11-19
HUE044595T2 (hu) 2019-11-28
IL193605A0 (en) 2011-08-01
NZ570878A (en) 2011-09-30
IL193605A (en) 2015-07-30
HK1120813A1 (en) 2009-04-09
US8187603B2 (en) 2012-05-29
WO2007098170A1 (en) 2007-08-30
CA2643226C (en) 2016-04-12
AR059604A1 (es) 2008-04-16
CN101426816A (zh) 2009-05-06
PT1991584E (pt) 2012-02-20
BRPI0708101B8 (pt) 2021-05-25
MX2008010708A (es) 2008-11-14
US8470993B2 (en) 2013-06-25
US20110275790A1 (en) 2011-11-10
DK3020729T3 (da) 2019-07-29
SI3020729T1 (sl) 2019-10-30
RU2008134137A (ru) 2010-03-27
DK1991584T3 (da) 2012-04-02
ES2738731T3 (es) 2020-01-24
SA07280062B1 (ar) 2012-03-13
KR101616712B1 (ko) 2016-04-29
KR20140100589A (ko) 2014-08-14
AU2007217751A1 (en) 2007-08-30
AU2007217751B2 (en) 2012-08-23
CR10237A (es) 2008-11-26
BRPI0708101A2 (pt) 2011-05-17
JP5150516B2 (ja) 2013-02-20
JP2009531023A (ja) 2009-09-03
CN101426816B (zh) 2012-12-12
ZA200807278B (en) 2009-05-27
US20130005033A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
BRPI0708101A8 (pt) anticorpos contra a il-22 humana e usos para eles
AR043616A1 (es) Anticuerpos contra receptor humano il-21 y usos de los mismos
BR112015029395A2 (pt) Anticorpos anti-b7-h5 e seus usos
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
NO20083697L (no) Fremgangsmater for anvendelse av antistoffer mot human IL-22
EA201171237A1 (ru) Антитела к dkk-1
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
BR112015017619A2 (pt) formulação líquida, uso de uma formulação, e, kit
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
EA201000424A1 (ru) Антитела к il-23
BRPI1014544B8 (pt) anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
EA201491656A1 (ru) Связывающие молекулы человека, способные связываться с вирусами гриппа в и нейтрализовать их, и их применения
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
AR072136A1 (es) Metodos de tratamiento que utilizan proteinas de union del receptor de in-terleuquina 21
BR112015014621A2 (pt) Anticorpos anti-h7cr
NZ701370A (en) Il-6 binding molecules
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112019007147A2 (pt) anticorpos anti-o1 e usos dos mesmos
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
MY149448A (en) Interleukin-21 receptor binding proteins
ECSP056015A (es) Anticuerpos contra el receptor de il-21 humano y usos de los mismos
TH97938A (th) แอนติบอดีต่อต้าน il-22 ของมนุษย์และวิธีการใช้สำหรับการนั้น
TH157534A (th) โปรตีนที่ยึดเหนี่ยว dll4 ที่รักษาโรค

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: WYETH LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF